Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2010
04/20/2010US7700554 Compositions for modulating blood-brain barrier transport
04/20/2010US7700549 treating Type II diabetes, eating disorders, and insulin-resistance syndrome with exendin peptide analogs of given amino acid sequence
04/20/2010US7700341 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
04/20/2010US7700304 inhibiting formation of neurofibrillary tangles by reducing formation of a carboxyl-terminal truncated form of apolipoprotein E (apoE) in a neuron in the individual; animal models of Alzheimer's disease (AD); treating AD; drug screening
04/20/2010US7700301 Using protein tyrosine phosphatase (SHP-2) as tool in identifying compounds which modulate the activity of programed death-1 (PD-1); treating autoimmune, nervous system, tumor and immunosuppressive disorders
04/20/2010US7700297 Artery- and vein-specific proteins and uses therefor
04/20/2010US7700274 Compositions and methods in cancer associated with altered expression of KCNJ9
04/20/2010US7700272 Ligand gated chloride channel for use as screening tool in identifying/screening pesticidal and antiparasitic agents
04/20/2010US7700271 Method of diagnosis and treatment and agents useful for same
04/20/2010US7700133 Antimicrobial formulations and methods of using the same
04/20/2010US7700128 a layer containing pioglitazone or pioglitazone hydrochloride; and a layer containing glimepiride and a polyoxyethylene sorbitan fatty acid ester ; useful as a diabetes-treating agent and excellent in the dissolution properties of an insulin sensitizer and an insulin releasing pills
04/20/2010US7700122 Topical compositions comprising an opioid analgesic and an NMDA antagonist
04/20/2010US7700121 Gene associated with leishmania parasite virulence
04/20/2010US7700120 Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus
04/20/2010US7700117 Camp factor of Streptococcus uberis
04/20/2010US7700115 immunogens, tripeptides, pentapeptides; inducing antibodies against diverse HIV clades and relate to ability to identify HIV gp120-derived short peptide sequence immunogens; Alzheimer's disease, psoriasis, multiple sclerosis
04/20/2010US7700106 Therapeutic agent for ulcerative colitis
04/20/2010US7700096 Medicinal agent for treating erectile dysfunction
04/20/2010US7700087 Compounds and methods to inhibit or augment an inflammatory response
04/20/2010US7700085 Administering an agent which inhibits binding of advanced glycation endproducts to any of their receptors; wound healing
04/20/2010US7700081 Psoriasis; applying daily to hair an aqueous mixture of clobetasol propionate, an anionic surfactant, an amphoteric surfactant, and ethanol; leaving it for 2.5 to 15 minutes, and rinsing with water.
04/20/2010US7699609 Dispensing apparatus and cartridge with deformable tip
04/20/2010CA2433409C Use of mglur5 antagonists for the treatment of pruritic conditions
04/20/2010CA2432178C Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
04/20/2010CA2393159C Methods of treating tumors
04/20/2010CA2388240C Phenoxy carboxylic acid compounds and compositions for delivering active agents
04/20/2010CA2359573C Conjugates of colony stimulating factors for targeting and imaging infection and inflammation
04/20/2010CA2358925C Compositions and methods for use in targeting vascular destruction
04/20/2010CA2348741C Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use
04/20/2010CA2319680C Compounds and compositions for delivering active agents
04/20/2010CA2287541C Regulatory system for inducible expression of genes with lambdoid promoters
04/20/2010CA2279331C Compounds and compositions for delivering active agents
04/20/2010CA2268358C Hormonal composition consisting of an oestrogen compound and of a progestational compound
04/15/2010WO2010042886A2 Pyrone analogs for therapeutic treatment
04/15/2010WO2010042714A1 Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
04/15/2010WO2010041449A1 Anti-allergic agent comprising rxr agonist as active ingredient
04/15/2010WO2010041400A1 Biofilm formation inhibitor
04/15/2010WO2010041140A2 Treatment of proliferative disorders with a death receptor agonist
04/15/2010WO2010040204A1 Detection of granulosa-cell tumors
04/15/2010WO2008124085A3 Methods of using combinations of mek and jak-2 inhibitors
04/15/2010US20100093870 Herbal medicaments for the treatment of neurocerebrovascular disorders
04/15/2010US20100093855 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
04/15/2010US20100093853 Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
04/15/2010US20100093839 hypoxia-inducible factor-1 alpha (HIP-1 alpha); nucleosides, Locked Nucleic Acids; treating kidney cancer, melanoma, glioblastoma and prostate cancer, and pre-eclampsia
04/15/2010US20100093797 Methods For Treatment Of Cognitive And Menopausal Disorders With D-Threo Methylphenidate
04/15/2010US20100093752 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors
04/15/2010US20100093708 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
04/15/2010US20100093683 Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a proteasome inhibitor
04/15/2010US20100093671 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
04/15/2010US20100093632 Enamel matrix protein composition for treatment of systemic inflammatory response
04/15/2010US20100093003 Methods to impair hematologic cancer progenitor cells and compounds related thereto
04/15/2010US20100092990 Nucleic acids encoding sodium channel scn1a alpha subunit proteins and mutations associated with epilepsy
04/15/2010US20100092579 Medicament for treating lung cancer
04/15/2010US20100092540 Drug delivery compositions and medical devices containing block copolymer
04/15/2010US20100092448 Local control of inflammation
04/15/2010US20100092445 Adoptive immune cells for tumor vaccines
04/15/2010US20100092435 Use of a varicellovirus tap-inhibitor for the induction of tumor-or virus-specific immunity against teipp
04/15/2010CA2740075A1 Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
04/15/2010CA2740046A1 Detection of granulosa-cell tumors
04/15/2010CA2740003A1 Pyrone analogs for therapeutic treatment
04/14/2010EP2174955A1 Ifnar2 muteins, their production and use
04/14/2010EP2174954A1 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
04/14/2010EP2174667A1 Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
04/14/2010EP2174662A2 Methods for treating muscle injuries
04/14/2010EP2174640A1 Protective agent against damage of biological tissue caused by near-infrared ray, and product comprising the same
04/14/2010EP2173876A2 T-cell cytokine-inducing surface molecules and methods of use
04/14/2010EP2173186A1 Compositions comprising polyphenol
04/14/2010EP1641473B1 Buffered compositions for dialysis
04/14/2010EP1423704B1 Diagnostic and therapeutic use of f-box proteins for alzheimer's disease and related neurodegenerative disorders
04/14/2010EP1409016B1 Antibodies to opgl
04/14/2010EP1406928B1 Ntb-a, a surface molecule involved in natural killer cells activity
04/14/2010EP1399483B1 Antibodies to insulin-like growth factor i receptor
04/14/2010EP1363636B1 A combination comprising levosimendan and a calcium source for the treatment of heart failure
04/14/2010EP1347773B1 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
04/14/2010EP1305418B1 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
04/14/2010EP1294922B1 Treating cancer using organelle crystallizing agents
04/14/2010EP1207199B1 Tumor antigen
04/14/2010EP0831903B1 Connective tissue growth factor
04/14/2010CN1778296B Long-acting preparation for tatin medicine
04/14/2010CN1777445B Agent for repairing corneal perception
04/14/2010CN1465338B Skin activating composition for external used anti-aging preparation
04/14/2010CN1346281B Use for preparing medicine used for the planned stimulation to controlled ovary
04/14/2010CN101693736A Novel peptides
04/14/2010CN101693672A Peptidomimetic protease inhibitors
04/14/2010CN101693107A Methods of treating neurological conditions with hematopoeitic growth factors
04/13/2010US7696403 Drug screening for an allergosis; screening an inducer/promoter or an inhibitor for Th2-mediated immune response or a promoter or an inhibitor for PIR-A function
04/13/2010US7696331 parenterally administering a dose of samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and carboplatin or taxoids; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders
04/13/2010US7696321 Molecules and methods for inhibiting shedding of KIM-1
04/13/2010US7696247 Lipid-based nitric oxide donors
04/13/2010US7696225 (2-carboxamido)(3-Amino) thiophene compounds
04/13/2010US7696197 having a calpain inhibiting activity and an activity which traps the reactive oxygen species (ROS); for protecting acoustic hair cells;
04/13/2010US7696189 ene steroids as anticarcinogenic agent
04/13/2010US7696180 Antisense oligonucleotide derivative as antitumor agent; biodrugs
04/13/2010US7696172 culture product produced by culturing a recombinant host cell under suitable conditions to express the polypeptide; has an oncogenic activity; treating liver disorder cirrhosis, or pancreas disorder
04/13/2010US7696151 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity
04/13/2010US7696148 An aerosol for the treatment of a microbial infection, comprising a sterile vehicle and a leukotriene dissolved in such vehicle, aerosol comprises a gaseous suspension of fine or liquid particles; treatment and prevention of bacterial pneumonia; pulmonary aerosolization
04/13/2010US7695903 diagnosing Alzheimer's disease by measuring abundance of low-density lipoprotein receptor related protein-1 (LRP-1), abundance of transcripts thereof, or LRP-1 receptor activity and comparing with an age-matched control
04/13/2010US7695742 Plant extract mixtures and their uses
04/13/2010US7695736 Powder of 30-90% a water-soluble cycloxygenase inhibitor, 5-60% of a buffer and 0-10% of other excipients
04/13/2010US7695730 Warming and nonirritating lubricant compositions and method of comparing irritation
1 ... 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 ... 1151